Viewing Study NCT04040231



Ignite Creation Date: 2024-05-06 @ 1:30 PM
Last Modification Date: 2024-10-26 @ 1:15 PM
Study NCT ID: NCT04040231
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-06-14
First Post: 2019-07-29

Brief Title: Using a Targeted Cancer Vaccine Galinpepimut-S With Immunotherapy Nivolumab in Mesothelioma
Sponsor: Memorial Sloan Kettering Cancer Center
Organization: Memorial Sloan Kettering Cancer Center

Study Overview

Official Title: Combining a WT1 Cancer Vaccine Galinpepimut-S With Checkpoint Inhibition Nivolumab in Patients With WT1-Expressing Malignant Pleural Mesothelioma A Phase I Study
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None